H.C. Wainwright lowered the firm’s price target on Stoke Therapeutics (STOK) to $35 from $47 and keeps a Buy rating on the shares after Stoke announced that the Phase 3 EMPEROR trial might begin around Q2. The EMPEROR trial is “designed for success, with robust methodology and global regulatory alignment supporting its credibility,” says the analyst, who is lowering the firm’s multiples and increasing discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk, leading to the firm’s reduced price target on Stoke shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics: Strategic Positioning and Financial Health Drive Buy Rating Amid Upcoming Phase 3 Trial for Dravet Syndrome Treatment
- Stoke Therapeutics’ Promising Outlook: Buy Rating Backed by Zorevenersen’s Potential and Strong Financial Position
- Stoke Therapeutics Advances with Strong Q1 2025 Results
- Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset
- Stoke Therapeutics: Strong Financial Position and Strategic Advancements Justify Buy Rating